Ko, Darae
Treu, Timothy M.
Tarko, Laura
Ho, Yuk-Lam
Preis, Sarah R.
Trinquart, Ludovic
Gagnon, David R.
Monahan, Kevin M.
Helm, Robert H.
Orkaby, Ariela R.
Lubitz, Steven A.
Bosch, Nicholas A.
Walkey, Allan J.
Cho, Kelly
Wilson, Peter W. F.
Benjamin, Emelia J.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K23HL151903-01A1, R01 HL136660, R01 HL139751, R01 HL151607, R01HL092577)
VA Merit Award (I01 CX001025)
American Heart Association (AF AHA_18SFRN34110082)
NIH (R01HL139731, R01HL157635)
National Center for Advancing Translational Sciences (1KL2TR001411)
Article History
Received: 7 May 2023
Accepted: 1 January 2024
First Online: 10 January 2024
Competing interests
: Drs. Ko and Helm report an investigator-initiated research grant from Boston Scientific Corporation to their institution. Dr. Ko reports consulting fee from Windrose Consulting Group. Dr. Orkaby reports consulting fees from Anthos Therapeutics. Dr. Lubitz is a full-time employee of Novartis Institutes of BioMedical Research as of July 18, 2022. Dr. Lubitz previously received sponsored research support from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Fitbit, Medtronic, Premier, and IBM, and has consulted for Bristol Myers Squibb, Pfizer, Blackstone Life Sciences, and Invitae. The other authors declare no competing interests.